MA69876A1 - Compositions pharmaceutiques comprenant de l'isotrétinoïne ainsi que leurs procédés de préparation et leurs utilisations - Google Patents

Compositions pharmaceutiques comprenant de l'isotrétinoïne ainsi que leurs procédés de préparation et leurs utilisations

Info

Publication number
MA69876A1
MA69876A1 MA69876A MA69876A MA69876A1 MA 69876 A1 MA69876 A1 MA 69876A1 MA 69876 A MA69876 A MA 69876A MA 69876 A MA69876 A MA 69876A MA 69876 A1 MA69876 A1 MA 69876A1
Authority
MA
Morocco
Prior art keywords
pharmaceutical compositions
well
compositions containing
preparation methods
isotretinoin
Prior art date
Application number
MA69876A
Other languages
English (en)
Inventor
Ashish ANVEKAR
Nagaprasad Vishnubhotla
Arun Jana
Original Assignee
Acrotech Biopharma Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Acrotech Biopharma Inc. filed Critical Acrotech Biopharma Inc.
Publication of MA69876A1 publication Critical patent/MA69876A1/fr

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/045—Hydroxy compounds, e.g. alcohols; Salts thereof, e.g. alcoholates
    • A61K31/07—Retinol compounds, e.g. vitamin A
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/16—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite containing nitrogen, e.g. nitro-, nitroso-, azo-compounds, nitriles, cyanates
    • A61K47/18—Amines; Amides; Ureas; Quaternary ammonium compounds; Amino acids; Oligopeptides having up to five amino acids
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/185—Acids; Anhydrides, halides or salts thereof, e.g. sulfur acids, imidic, hydrazonic or hydroximic acids
    • A61K31/19—Carboxylic acids, e.g. valproic acid
    • A61K31/20—Carboxylic acids, e.g. valproic acid having a carboxyl group bound to a chain of seven or more carbon atoms, e.g. stearic, palmitic, arachidic acids
    • A61K31/203—Retinoic acids ; Salts thereof
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/06—Organic compounds, e.g. natural or synthetic hydrocarbons, polyolefins, mineral oil, petrolatum or ozokerite
    • A61K47/22—Heterocyclic compounds, e.g. ascorbic acid, tocopherol or pyrrolidones
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/44—Oils, fats or waxes according to two or more groups of A61K47/02-A61K47/42; Natural or modified natural oils, fats or waxes, e.g. castor oil, polyethoxylated castor oil, montan wax, lignite, shellac, rosin, beeswax or lanolin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4816—Wall or shell material
    • A61K9/4825—Proteins, e.g. gelatin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4833—Encapsulating processes; Filling of capsules
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4858—Organic compounds
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K9/00—Medicinal preparations characterised by special physical form
    • A61K9/48—Preparations in capsules, e.g. of gelatin, of chocolate
    • A61K9/4841—Filling excipients; Inactive ingredients
    • A61K9/4875—Compounds of unknown constitution, e.g. material from plants or animals
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P17/00—Drugs for dermatological disorders
    • A61P17/10—Anti-acne agents

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Epidemiology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Zoology (AREA)
  • Botany (AREA)
  • Oil, Petroleum & Natural Gas (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Dermatology (AREA)
  • Organic Chemistry (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Preparation (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)

Abstract

La présente invention concerne une composition pharmaceutique orale hautement dosée à charge médicamenteuse élevée d'isotrétinoïne avec faible poids de remplissage, et des capsules de taille réduite. La présente invention concerne également des procédés de préparation des compositions pharmaceutiques orales divulguées et des méthodes de traitement d'affections et de troubles tels que des troubles cutanées, y compris l'acnée, par l'administration desdites compositions pharmaceutiques par voie orale à un patient dont l'état le nécessite.
MA69876A 2022-07-01 2023-06-27 Compositions pharmaceutiques comprenant de l'isotrétinoïne ainsi que leurs procédés de préparation et leurs utilisations MA69876A1 (fr)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
IN202221038020 2022-07-01
PCT/US2023/069155 WO2024006748A1 (fr) 2022-07-01 2023-06-27 Compositions pharmaceutiques comprenant de l'isotrétinoïne ainsi que leurs procédés de préparation et leurs utilisations

Publications (1)

Publication Number Publication Date
MA69876A1 true MA69876A1 (fr) 2025-11-28

Family

ID=89381622

Family Applications (1)

Application Number Title Priority Date Filing Date
MA69876A MA69876A1 (fr) 2022-07-01 2023-06-27 Compositions pharmaceutiques comprenant de l'isotrétinoïne ainsi que leurs procédés de préparation et leurs utilisations

Country Status (15)

Country Link
US (3) US12016830B2 (fr)
EP (1) EP4547241A1 (fr)
JP (1) JP2025534534A (fr)
KR (1) KR20250054055A (fr)
CN (1) CN119789850A (fr)
AU (1) AU2023301386A1 (fr)
CA (1) CA3261044A1 (fr)
CL (1) CL2025000011A1 (fr)
CO (1) CO2025001171A2 (fr)
IL (1) IL318115A (fr)
JO (1) JOP20250001A1 (fr)
MA (1) MA69876A1 (fr)
MX (1) MX2025000038A (fr)
PE (1) PE20251522A1 (fr)
WO (1) WO2024006748A1 (fr)

Families Citing this family (1)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2024006748A1 (fr) 2022-07-01 2024-01-04 Acrotech Biopharma Inc. Compositions pharmaceutiques comprenant de l'isotrétinoïne ainsi que leurs procédés de préparation et leurs utilisations

Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2001095886A1 (fr) * 2000-06-16 2001-12-20 Ranbaxy Laboratories Limited Forme galenique biodisponible d'isotretinoine
WO2002024172A1 (fr) * 2000-09-22 2002-03-28 Galephar M/F Composition pharmaceutique semi-solide d'isotretinoine
US20050129773A1 (en) * 2001-12-06 2005-06-16 Inderdeep Bhatia Isotretinoin nanoparticulate compositions
US20060264504A1 (en) * 1997-08-23 2006-11-23 Werner Bollag Treatment of cell-mediated immune diseases
WO2016051288A1 (fr) * 2014-10-01 2016-04-07 Sun Pharmaceutical Industries Limited Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
WO2016193779A1 (fr) * 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Composition pharmaceutique orale d'isotrétinoïne
KR102108153B1 (ko) * 2017-07-05 2020-05-07 (주)동구바이오제약 생체 이용률 및 안정성이 개선된 레티노이드를 함유하는 약제학적 조성물

Family Cites Families (15)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4322438A (en) 1979-08-06 1982-03-30 United States Of America Method for the use of orally administered 13-cis-retinoic acid in the treatment of acne
DK0563112T3 (da) * 1990-12-18 1995-04-10 Merrell Dow Pharma Probucol-holdigt lægemiddel med forøget biotilgængelighed
PE20001227A1 (es) 1998-10-30 2000-11-06 Hoffmann La Roche Procesos para producir una composicion de isotretinoina
US7374779B2 (en) * 1999-02-26 2008-05-20 Lipocine, Inc. Pharmaceutical formulations and systems for improved absorption and multistage release of active agents
CA2515440A1 (fr) * 2003-02-12 2004-09-02 L'oreal Utilisation d'un inhibiteur de 15-hydroxy prostaglandine deshydrogenase pour favoriser la pigmentation de la peau ou des phaneres
US20070014847A1 (en) * 2005-07-05 2007-01-18 Ahmed Salah U Coated capsules and methods of making and using the same
CN102802729A (zh) 2009-05-20 2012-11-28 兰贝克赛实验室有限公司 异维a酸的液体剂型
RU2016150863A (ru) 2014-05-29 2018-07-03 Сан Фармасьютикал Индастриз Лимитед Пероральная фармацевтическая композиция изотретиноина
BR112016028316A2 (pt) * 2014-06-02 2017-08-22 Sun Pharmaceutical Ind Ltd composição farmacêutica oral de isotretinoina, seu processo de preparação e método de tratamento
AU2015294993A1 (en) 2014-07-31 2017-02-16 Sun Pharmaceutical Industries Limited Oral pharmaceutical composition of isotretinoin
US9750711B2 (en) 2014-10-01 2017-09-05 Sun Pharmaceutical Industries Limited Low dose oral pharmaceutical composition of isotretinoin
WO2016189481A1 (fr) 2015-05-25 2016-12-01 Sun Pharmaceutical Industries Limited Composition pharmaceutique orale à dosage quotidien unique
CN105535979B (zh) * 2015-11-22 2019-06-25 李素华 一种提高难溶药物生物利用度的自微乳化载药系统及其应用
EP3257499A1 (fr) 2016-06-17 2017-12-20 Vipharm S.A. Procédé pour la préparation de capsules de méthanesulfonate d'imatinib
WO2024006748A1 (fr) 2022-07-01 2024-01-04 Acrotech Biopharma Inc. Compositions pharmaceutiques comprenant de l'isotrétinoïne ainsi que leurs procédés de préparation et leurs utilisations

Patent Citations (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US20060264504A1 (en) * 1997-08-23 2006-11-23 Werner Bollag Treatment of cell-mediated immune diseases
WO2001095886A1 (fr) * 2000-06-16 2001-12-20 Ranbaxy Laboratories Limited Forme galenique biodisponible d'isotretinoine
WO2002024172A1 (fr) * 2000-09-22 2002-03-28 Galephar M/F Composition pharmaceutique semi-solide d'isotretinoine
US20050129773A1 (en) * 2001-12-06 2005-06-16 Inderdeep Bhatia Isotretinoin nanoparticulate compositions
WO2016051288A1 (fr) * 2014-10-01 2016-04-07 Sun Pharmaceutical Industries Limited Composition pharmaceutique d'isotrétinoïne à faible dosage destinée à la voie orale
WO2016193779A1 (fr) * 2015-05-29 2016-12-08 Sun Pharmaceutical Industries Limited Composition pharmaceutique orale d'isotrétinoïne
KR102108153B1 (ko) * 2017-07-05 2020-05-07 (주)동구바이오제약 생체 이용률 및 안정성이 개선된 레티노이드를 함유하는 약제학적 조성물

Also Published As

Publication number Publication date
CA3261044A1 (fr) 2024-01-04
PE20251522A1 (es) 2025-06-05
CL2025000011A1 (es) 2025-06-23
JOP20250001A1 (ar) 2025-01-02
AU2023301386A1 (en) 2025-01-23
US12016830B2 (en) 2024-06-25
JP2025534534A (ja) 2025-10-16
CO2025001171A2 (es) 2025-04-28
EP4547241A1 (fr) 2025-05-07
CN119789850A (zh) 2025-04-08
US20240293338A1 (en) 2024-09-05
US20240000722A1 (en) 2024-01-04
KR20250054055A (ko) 2025-04-22
MX2025000038A (es) 2025-05-02
US20260102361A1 (en) 2026-04-16
WO2024006748A1 (fr) 2024-01-04
US12527750B2 (en) 2026-01-20
IL318115A (en) 2025-02-01

Similar Documents

Publication Publication Date Title
BR112017010551A2 (pt) composto, métodos para ativação de guanilato ciclase solúvel, para tratamento de uma ou mais condições selecionadas a partir de uma doença em um paciente e para tratamento de uma doença ou condição, composição farmacêutica, uso de um composto, e, medicamento.
MX2019011491A (es) Formulaciones de niraparib.
CN1092973C (zh) 乳香或乳香亲脂性提取物在制备用于治疗阿尔茨海默症的药物中的用途
WO2023088497A3 (fr) Dérivé de béraprost du type donneur d'oxyde nitrique et composition pharmaceutique et leur utilisation
PH12021553056A1 (en) Modified release formulations and uses thereof
BR112021021029A2 (pt) Preparação de canabidiol, e, método para tratar um paciente que sofre de crises associadas ao complexo de esclerose tuberosa
EP4410295A3 (fr) Utilisation de vibegron pour traiter une vessie hyperactive
MX2025002790A (es) Derivados de piperidina 2-sustituidos, metodos de preparacion y usos medicinales de los mismos
CN104013638B (zh) 当药黄素及其衍生物的用途
NZ526041A (en) Method and composition for the treatment of diabetic neuropathy
MX2013003523A (es) Composicion farmaceutica de dosis baja.
WO2021022058A3 (fr) Formulation antiarythmique
US20240082219A1 (en) Methods for ameliorating and preventing age-related muscle degeneration
EP4494705A3 (fr) Agonistes de récepteur non peptidique d'oxytocine
MX2025000038A (es) Composiciones farmacéuticas que comprenden isotretinoína y procesos para la preparación y usos de las mismas
EP2575807A1 (fr) Formulation à base de sulpiride et d'une composition homéopathique synergique destinée au traitement d'un syndrome dépressif
JP5961034B2 (ja) 安定化方法
WO2022204344A3 (fr) N-oxydes d'énamine : synthèse et application à des promédicaments sensibles à l'hypoxie et agents d'imagerie
BR112017019753A2 (pt) uso de composições de astaxantina, composição, processo para preparação de um produto alimentício ou ração, e, preparação medicinal
Brown et al. GBT021601, a next generation HbS polymerization inhibitor: results of safety, tolerability, pharmacokinetics and pharmacodynamics in adults living with sickle cell disease and healthy volunteers
JP5984328B2 (ja) 独活葛根湯エキス配合剤
EP4620940A3 (fr) Synthese de (+)-cannabinoides et leurs effets therapeutiques
MX2024008873A (es) Usos y metodos para promover el aumento de la masa y funcion mitocondrial.
MX2010006310A (es) O-desmetil-venlafaxina para el tratamiento de transtorno depresivo mayor.
CA2917081C (fr) Utilisation de l'homogenat de couvain de faux-bourdons adsorbe et de vitamine d3 ou de vitamines du groupe d et/ou de leurs metabolites actifs pour la prevention et le traitement des maladies virales